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1.  Executive Summary 
Intranasal drug delivery is an alternative method in addition to traditional oral and intravenous 
doses. Nasal drug delivery has proven to be a very effective technique for nicotine cessation 
(Hjalmarson et al., 1994), the influenza vaccine (Jackson et al. 1999), and drugs that need to be 
take continuously, such as insulin (Dondeti et al., 1995).  
Studies have found that for effective fast-acting body response, the drug needs to be deposited in 
the highly vascularized mucosal tissue lining the bony turbinates in the nasal cavity. Commercial 
nasal sprays are continuously optimizing parameters to develop the most effective deposition 
patterns.  
In  this  project,  drug  deposition  is  modeled  using  a  simplified  2D  depiction  of  the  nasal 
passageway with uniformly-shaped, spherical spray particles. This problem is implemented in 
COMSOL by using 2D Navier Stokes fluid flow equations to model the airflow through the nose, 
and the Particle Tracing module to model the spray trajectory and deposition.   
The model output was validated by determining the percentages of particles in each region of the 
nasal  passage  –  anterior,  turbinate,  posterior,  and  outlet  –  and  comparing  with  published 
experimental data by Cheng et al (2001).   
A  sensitivity  analysis  was  done  on  the  following  parameters:  particle  density,  particle  size, 
nozzle spray angle, and nozzle penetration depth. It was found that this model was sensitive to 
only penetration depth. As penetration depth through the nostril increased, there was a decrease 
in  the  particle  deposition  in  the  anterior  region  of  the  nasal  cavity  and  an  increase  in  the 
percentage of particles that exited through the outlet. Deposition in the middle and posterior 
regions was not affected by variation in penetration depth. Our sensitivity analysis demonstrated 
that  variations  in  spray  angle,  particle  size,  and  density  of  the  nasal  spray  fluid  do  not 
significantly affect deposition pattern. Therefore, when designing nasal sprays, as long as these 
parameters remain within the specified ranges, consistent deposition patterns will be achieved. 
This result also allows for further research on creating sprays that are more concentrated and 
have encapsulated drugs.  
Keywords: intranasal spray, particle deposition, drug delivery 
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2.  Introduction 
The nasal cavity contains three turbinates, which are long shelves of spongy bone that divide the 
nasal passage into three airways. These airways are lined by mucosa, a highly vascularized tissue 
with openings to the paranasal sinuses. It has been hypothesized that drug deposition onto the 
mucosa lining of these turbinates can potentially treat health problems such as lung diseases, 
cancers, diabetes, and sinus infections (Inthavong et al. 2008). This has motivated many studies 
about nasal drug delivery systems (Cheng et al, 2001; Kimbell et al, 2007; Pringels et al, 2006; 
Sharma et al, 2009).   
Drug delivery through the use of nasal sprays is a unique alternative to the more traditional oral 
or intravenous administration of drugs. Nasal sprays can produce a faster response to the blood 
stream or area of interest than oral applied drugs, and does not degrade the drug as it travels 
through the digestive system (Inthavong et al. 2008).   
The  liquid  mixture  of  nasal  sprays  is  converted  to  a  fine  spray  composed  of  micron-sized 
particles.  These particles enter the nostril, travel through the nasal cavity, and deposit within the 
passage way. It has been found that the majority of drug material is deposited within the anterior 
portion of the nose; however, this is disadvantageous as this area contains filters and narrow 
passageways to restrict large drug particles from being absorbed within the more vascularized 
mucosal walls. Deposition in the mucosal walls of the turbinates would allow the drug to diffuse 
into the blood stream and provide relief for a patient (Inthavong et al. 2008). 
Inthavong et al. (2008) performed a study to determine the parameters important in designing a 
nasal  drug  delivery  device.  In  order  to  do  this,  two  visualization  systems  were  used:  (i)  a 
particle/droplet image analyzer (PDIA), and (ii) particle image velocimetry (PIV).  The PDIA 
provides  detailed  imaging  of  the  spray  and  formation  of  droplets  and  the  PIV  gives  an 
approximate velocity field. The researchers used FLUENT and employed the Lagrangian particle 
movement equations to trace the dispersion and trajectory of particles. They determined that the 
parameters particle size, diameter of spray cone at a break-up length, and spray cone angle had 
significant effects on deposition. 
Since the effects of spray cone angle and diameter of spray cone at break-up length have already 
been determined, we examined other parameters. We used the same equations (Inthavong et al.  
 
5 
 
2008)  to  model  movement  of  particles  in  our  simulation  and  have  examined  the  effects  of 
particle size and density, as well as the angle and penetration depth of spray nozzle insertion.  
2.1 Design Objectives 
We will determine nasal spray particle deposition within a simplified nasal cavity geometry by 
modeling airflow through the nasal passage along with the movement of particles. Our objective 
is to examine the effects of particle size, particle density, spray angle, and penetration depth of 
spray  nozzle  on  the  pattern  of  spray  deposition.  These  terms  are  defined  below  in  Problem 
Formulation. Ultimately, our goal is to determine what combination of spray size, density, angle, 
and penetration depth will lead to an optimal spray deposition within the turbinate region. Our 
findings can then be used to inform future designs of nasal spray delivery systems.   
3.  Problem Formulation 
3.1 Terms Defined 
Particle  Size  refers  to  the  diameter  chosen  for  the  particle  sphere.  We  have  modeled  drug 
particles as uniform spheres as this corresponds to the shape of the spray exiting the nozzle. 
From literature research, it was determined that the range of particle size is 10-70µm (Inthavong 
et al., 2007; Kimbell et al., 2007). We have chosen our baseline particle size to be 50µm. 
Particle Density refers to the apparent density of each nasal spray droplet. This parameter would 
take into account the weighted averages of all spray particle components. For this study, we have 
chosen a baseline value of 1000 kg/m
3, the density of water (Inthavong et al. 2008).  
Spray Angle refers to the particle angle that exits the nozzle upon applying pressure to the 
container. This parameter was varied when changing the initial velocity of the particle in both the 
x and y direction. The baseline condition was 45˚.   
Penetration Depth refers to the initial depth at which the spray nozzle is inserted into the nose. 
As there are restrictions for this depth, we chose the baseline condition at the inlet of the nose at 
a depth corresponding to zero.   
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3.2 Schematic 
We are using COMSOL to model the nasal cavity in two dimensions.   A complete schematic of 
our model with  boundary  conditions  and property values  is  shown below (Figure 1).   The 
geometry of the nasal cavity was simplified to include only the lower turbinate, neglecting flow 
above the middle turbinate, based on the assumption that drug flow occurs predominantly around 
the  lower  turbinate.  Figure  2  shows  a  more  anatomical,  3D  representation  of  the  nasal 
passageway.  
 
 Figure 1. Schematic used in COMSOL modeling showcasing all dimensions.  
 
 
Figure 2. Actual 3 dimensional geometry of nasal cavities. (a) Taken from Inthavong et al. 2008; (b) Taken from 
Wikipedia under the GNU Free Documentation License. Note, nasal concha is another term for the nasal turbinate folds. 
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3.3 Mesh 
We used an unstructured mesh, with an “extra fine” predefined mesh size, shown in Figure 3. 
This mesh contained 4624 triangular elements. 
 
Figure 3. Unstructured mesh of nasal cavity, containing 4624 triangular elements. Predefined mesh size was extra fine. 
3.4 Governing Equations 
The lower region of the nasal passage way was determined by literature research with accurate 
dimensions (Inthavong et al., 2008). To model the intake of air via the nose, the Navier Stokes 
equation was used to describe air as an incompressible fluid. The 2D Navier-Stokes and steady 
state continuity equations in Cartesian coordinates are shown in Appendix A (Datta and Rakesh 
2008). 
To  account  for  the  drug  particles  within  the  nasal  spray,  the  velocity  of  the  particles  were 
determined with the Lagrangian equations shown in Appendix A (Inthavong et al. 2008).  
3.5 Boundary Conditions 
The  boundary  conditions  used  in  our  model  are  shown  in  Figure  4,  below.  This  is  a 
representation  of  our  boundary  conditions.    At  the  nostril  inlet,  we  have  a  constant  airflow 
velocity.  At the outlet going into the pharynx, we have a neutral condition, which translates to 
zero pressure in  this  case. All  other boundaries  have a no slip condition and 100% particle  
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trapping. We have divided the nasal cavity into the anterior, turbinate, and posterior portions. 
Spray is most often deposited in the anterior of the nasal cavity, but ideally deposition is desired 
in the vascularized mucosal lining of the turbinates. 
  
Figure  4.  COMSOL  geometry  boundaries.  Left  inlet  has  constant  velocity  boundary  conditions  in  equal  x  and  y 
components, resulting in a 45˚ angle. The nasal spray is inserted at the same angle, and also has a constant spray velocity. 
At the right (outlet), we have a neutral boundary condition to account for drug particles leaving he nasal passageway to 
the pharynx. All other boundaries are set to no slip for air flow, and 100% particle trapping for nasal spray particles. 
3.6 Assumptions  
(Inthavong et al. 2008) 
Fluid Flow 
1.  Inspiratory flow rate of 15 L/min (0.9 m/s) 
2.  Gravity was negligible in air and particle flow 
3.  Plug flow imposed at the nostrils 
4.   No slip condition at the walls  
5.  Laminar Flow 
6.  Normal velocity gradient was set to 0 at the outlet  
7.  Nasal walls were rigid (neglecting mucous movement and nasal hairs) 
Particles 
8.  Uniform size  
9.  Approximated as spheres 
10. Same density as water  
11.  Trapped with 100% efficiency upon touching the wall  
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12.  Brownian and Saffman lift forces were neglected 
13. Spray was inserted into the nose and directed parallel to the nasal passage 
3.7 Input Parameters 
The input parameters and units that we used are shown in Table 1. Initial velocity is split into its 
x-component,  u,  and  y-component,  v.  The  subscript  p  denotes  particles,  and  the  subscript  g 
denotes  the  fluid  (gas  phase).  The  inlet  air  velocity  at  the  nostrils  during  breathing  was 
previously shown to be approximately 0.90 m/s (Inthavong et al. 2008). We assumed a 45° angle 
for the direction of flow for incoming air, and calculated the component vectors to be 0.63 m/s in 
both the x and y directions. Since the nasal spray particles are very small, we used the same 
initial velocities for both particles and air. 
Table 1. Input parameters and units. 
Particle Density  ρp  1000  kg/m
3  Inthavong et al. 2008 
Particle Diameter  dp  50  μm  Inthavong et al. 2008 
Initial Particle Velocity 
vp  0.63  m/s 
Inthavong et al. 2008 
up  0.63  m/s 
Initial Fluid Velocity 
vg  0.63  m/s 
Inthavong et al. 2008 
ug  0.63  m/s 
Drag Force Coefficient  Cd  0.44     Holland et al. 1995 
Fluid Viscosity at 290K  μg  1.7985 x 10
-5  kg/ms 
Datta and Rakesh 2008 
Fluid Density at 290K  ρg  1.2177  kg/m
3 
         
Calculated Parameters (Inthavong et al. 2008) 
 
Reynolds Number  Rep  7839    
 
Drag Force per unit 
particle mass and per 
unit velocity difference 
between particle and 
fluid 
Fd  4.65248 x 10
5  1/s* 
 
Mass of Particle  mp  5.236 x 10
-13  kg 
 
 
*Units explained in Appendix A – Particle Velocity  
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4.  Results and Discussion 
4.1 Results  
We  used  COMSOL  to  simulate  nasal  spray  deposition  in  a  simplified  2D  geometry  at  the 
following baseline conditions:  a particle size of 50 µm, particle density of 1000 kg/m
3, inlet 
particle angle of 45˚, and penetration depth of 0 cm. We simulated 2 seconds of inhalation with a 
0.1 second time step in COMSOL.   Figure 9 is a plot of fluid velocity with respect to time at the 
point (0.03, 0.02) in our model. We chose this point because it was at the anterior-turbinate 
interface, potentially a region of high variability. In the plot, the fluid velocity reaches steady 
state well before the 2-second simulation time, at approximately 0.5 seconds. Figure 10 shows 
the results of a surface plot and particle tracing 2 seconds after the start of the simulation. The 
black lines show the trajectories of the particles and the pink circles show the final deposition 
location. In this baseline condition, it can be seen that most particle deposition occurred in the 
anterior region.  
Figures  11  and  12  show  magnified  images  of  the  anterior  and  posterior-outlet  regions, 
respectively, showing that particles had become trapped in eddy currents. At the outlet, a few 
particles still follow the eddy current while others are carried to the pharynx. Although many 
Computational  Fluid  Dynamics  models  have  employed  a  no  slip  condition  at  the  interior 
boundaries, this may not be a valid assumption. The no slip condition requires that velocity at the 
walls be set to zero, resulting in particle trajectories that never touch the wall in certain areas. 
Furthermore, this tendency for particles to not touch the wall – and subsequently be trapped –  
within the cavity results in more particles being carried to the outlet.  
We also examined the effects of penetration depth of the spray nozzle into the nasal cavity. 
Figure 13 shows a surface plot of these results. We observed that with an increased penetration 
depth, more particles were carried to the outlet and fewer particles followed eddy currents, when 
compared to the baseline condition. 
4.2 Limitations of Results  
During the modeling process, we determined that the particle tracing function had limitations 
whereby certain parameters resulted in COMSOL fatal memory errors. These errors arose when 
obtaining a solution with a large mesh size at a variety of particle sizes. The errors were reduced  
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when using a smaller mesh size of fewer elements but still resulted in errors when the particle 
size was  below 50 µm.  In order to  obtain results,  the resolution  size  in the particle tracing 
module had to be decreased to 1, as computation was not possible with higher resolutions. Due to 
memory limitations of COMSOL, we were not able to run the model with a refined mesh and 
small particle sizes of 50µm and below as suggested by literature research. The input parameters 
for the working model are however still within range of the literature research.  
4.3 Model Validation 
In order to perform an accuracy check on our nasal passage model, we compared our results to a 
study conducted by Cheng et al. (2001) that quantified particle deposition in the nasal cavity. 
These researchers were able to do so by making an acrylic replica of a human nasal cavity and 
testing four commercially available nasal sprays with varying cone angles in their model.  Cheng 
et al. (2001) elected to test sprays with various cone angles to examine its effect on particle 
deposition.  The deposition varies greatly because of the cone angle difference, since if a spray 
disperses  faster,  more  deposition  would  occur  early  in  the  anterior  region.  Spray  deposition 
percentage into the 3 main regions of the nasal cavity: anterior, turbinate and posterior region 
was quantified by radiolabeling the nasal spray.  Results from the Cheng et al. (2001) study 
(Figure 5) illustrate that most of the spray deposition occurs in the anterior and turbinate regions.    
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Using the particle tracking function in COMSOL, we were able to visualize the locations of the 
deposition and perform the same analysis to compare our model with results from this paper.  
Our model tracked 19 particles from the nostril inlet. We found that 63.2% of the particles were 
deposited into the anterior portion, 5.26% in the turbinates, 5.26% in the posterior portion and 
26.3%  exited  through  the  outlet  (Figure  5).  We  see  that  our  results  for  the  anterior  portion 
essentially mimic the results from the PF-80 (Cone Angle: 70°) nasal spray types used in the 
Cheng et al. (2001) study at 59.4%; however, we found a significant difference in percentage of 
the particles carried to the outlet. This can be attributed to the fact that the air flow velocities in 
the two studies varied (Q, or flow rate, varied by 5 L/min). Furthermore, differences between the 
experimental study and our model are likely due to the fact that there is an upper turbinate in the 
experimental setup, which has a more accurate 3D geometry from MRI scans. The difference in 
deposition in the turbinate region is likely because the  experimental 3D geometry had more 
surface area in this region for the particles to deposit. 
4.4 Sensitivity Analysis 
For our sensitivity analysis, we examined the effects of the following parameters: spray angle, 
penetration depth, particle size, and density of the nasal spray. Our initial values for the study for 
Figure 5. Four commercial sprays (VP-7, PF-35, PF-60, and PF-80) of various cone angles were tested to demonstrate 
nasal spray deposition patterns (Cheng et al. 2001). Results from our model were superimposed onto their data. 
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density, spray angle, particle size and penetration depth were 1000 kg/m
3, 45°, 50 µm diameter 
and 0 cm (level of nostril inlet), respectively.  Spray angle, particle size, and density of the nasal 
spray  fluid  were  varied  in  a  range  of  the  baseline  value  ±40%.  We  also  tested  3  different 
penetration depths: 0, 0.5cm, and 1.0 cm into the nostril. We were able to perform the sensitivity 
analyses by tracing the particles to specific regions defined in the nasal geometry: the anterior 
(front) portion before the turbinates, the middle turbinate region, the posterior region following 
the turbinates, and the nasal passage outlet (Figure 4).  We counted the particles in each of the 
regions and displayed the data (Figure 6) as a percentage of the total particles in the system.   
We  found  that  the  resulting  particle  deposition  pattern  was  insensitive  to  all  of  the  tested 
parameters except for penetration depth. Increasing penetration depth into the nostril results in an 
increased percentage of particles that exit through the outlet, while decreasing deposition in the 
anterior region of the nasal cavities; however, deposition in the middle and posterior regions 
were relatively insensitive to  variation in  penetration depth. The changes  due to  penetration 
depth  are  expected  because  by  decreasing  the  distance  between  the  deposition  area  and  the 
nozzle inlet, it is easier for the particles to begin flowing with the inhaled air than if the particles 
were sprayed directly at the level of the nostril inlet.   
 
  
 
14 
 
Figure 6. Results for sensitivity analysis.  The parameters that we varied were particle density, spray angle, particle size 
and penetration depth.  We varied the particle density, spray angle and particle size in 20% and 40% increments from 
the initial.  We varied penetration depth from the bottom of the nostril in 5mm and 1cm increments.  Sensitivity analyses 
were done by observing the percentage of particles depositing in the following regions in the nasal cavity: anterior (front), 
middle (turbinate), posterior (back) and through the passage outlet. 
5.  Conclusions and Design Recommendations 
Nasal sprays are an alternative method for drug delivery compared to oral and IV administration. 
This method has been applied to cold and allergy symptoms, flu vaccinations (Jackson et al. 
1999), smoking cessation (Hjalmarson et al., 1994), and migraine headaches (Graff and Pollack, 
2005). Recent work has been done for those who suffer from diseases where daily administration 
of drugs is necessary, such as diabetes patients. Recently, nasal sprays have been researched for 
delivery of insulin via enhancer molecules (Dondeti et al., 1995).  
These treatments have been effective as nasal drug delivery provides a faster response to the 
blood stream and avoids the GI tract where drugs can degrade. This avoidance also lessens the 
nauseous feelings and vomiting that occurs with oral drugs. Additionally, because of the ease of 
use, there is high patient compliance with nasal sprays as they are less painful and provide fast 
relief (Inthavong et al. 2008).  
5.1 Implications and Relevance 
Our sensitivity analysis reveals  that particle motion in the nasal passage does not vary with 
changes in particle size and density, leading us to conclude that intranasal drug delivery can be 
applied to many different kinds of drug particles with varying sizes and densities.  Due to this 
finding, there is a great potential to package many different types of drugs for rapid delivery to 
the bloodstream or area of interest.  Implications to this design can be applied to immune system 
recognition, encapsulation techniques and nanofabrication.  
Drugs targeted to the immune system, such as vaccinations, require time for the immune system 
to  actively  recognize  the  antigen  presented  to  the  bloodstream.  Therefore,  spray  powder 
formulations  have  been  proposed  to  allow  for  more  time-dependent  vaccine  delivery  in  the 
mucosa. This can be accomplished by coating the antigen or drug molecule in materials such as 
starch and poly(acrylic acid) (Coucke  et al. 2009).  It has also been shown that chitosan, a 
material derived from a naturally occurring polysaccharide with low cytotoxicity, can also serve 
as an encapsulation material. Chitosan is a unique biological material as it has the ability to  
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temporarily open tight junctions in the epithelial cell layer to allow for better delivery into the 
blood vasculature. Additionally, nanofabrication techniques have been applied in to nasal spray 
delivery with respect to the self-assembly of liposome drug encapsulations. This would account 
for more lipid-soluble drugs in the nasal mucosa (Sharma et al. 2009).   
In  each  of  these  systems,  the  encapsulation  process  increases  the  size  of  the  particulates. 
However, our study observed that deposition is insensitive to particle size and density, so larger 
drugs will have the same particle deposition patterns as smaller drugs. Larger drugs have further 
advantages  as  the  particle  load  can  be  protected  from  first  line  defense  mechanisms  of  the 
immune system. The particle size does have to be within a range as it will otherwise not diffuse 
through the mucosal layers for effective relief.   
5.2 Design Recommendations 
We were able to determine that our model was insensitive to particle size, particle density and 
spray angle.  This allows for flexibility in drug design.  For example, drugs can be loaded into 
protective coatings that increase the load size without affecting the particles’ flow in the nasal 
passage.  This finding shows that nasal sprays can be utilized to deliver larger particles with a 
consistent  deposition pattern, including polymer or chitosan encapsulations.  Because particle 
density does not play such a role in the intranasal model, several drug formulations can be used, 
allowing patients to choose a less invasive drug delivery method if shots are not an option due to 
fear  or  even  in  an  extreme  case,  hemophilia.    An  insensitivity  to  spray  angle  is  significant 
because at the user level, a patient administering the drug would not need extensive training to 
use a nasal spray device.  The spray nozzle would have to be inserted into the nostril and drug 
could be delivered without mention of not delivering enough or too much drug per dose.  This 
finding provides a user-friendly interface that is more universal since all people may either spray 
differently or have slightly different nasal geometry.   
Another important consideration for design of intranasal sprays lies in the user interface because 
our model was very sensitive to penetration depth.  Since penetration depth can affect the model 
so greatly, a nasal spray should be designed with a stopper outside of the nozzle to indicate the 
optimum penetration depth.  A nasal spray would need such control of this variable in order to be 
an effective drug delivery method.  Because penetration depth affects the model greatly, it could 
be possible to administer the drug to certain tissues using our simulation methods.  In order to  
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target the central nervous system, the olfactory bulb in the nasal cavity would provide a more 
direct way to bypass the blood-brain barrier (Graff et al. 2005).  A simulation in this case could 
return an optimal penetration depth at which drug deposition occurs mostly at the olfactory bulb 
region.  Also, it was stated that the most favorable target in the respiratory tract for drug delivery 
to systemic circulation was in the alveolar region, especially due to a large absorptive surface 
(Laube 2005).  As we increased penetration depth, more particles were exiting through the outlet 
and thereby depositing past the nasal mucosa and into the lower respiratory tract.  Due to this, we 
propose that a CFD simulation could also help target the systemic circulation. 
5.3 Design Constraints 
In modeling the nasal passageway to observe drug deposition, we were limited by COMSOL 
memory usage and simplified geometry. We were able to implement the Navier Stokes equation 
to account for air flow but had trouble with accurate particle quantification. In many trials when 
using the Particle Tracing function, we encountered fatal errors due to maximum memory usage. 
This occurred even with low resolution and few numbers of particles.  
We also simplified our model and compressed the geometry to only account for one nostril in 2D 
with only a lower turbinate, neglecting the upper turbinate fold.  As the turbinate folds were 
evaluated as perfect rectangular obstructions in the nasal passageway, the fluid flow resulted in 
eddy currents. Furthermore, as our model for nasal deposition and geometry was approximated 
based  on  nasal  images  of  a  single  person’s  nasal  cavity,  we  are  not  modeling  a  universal 
population.    However,  our  studies  give  us  a  general  picture  of  nasal  air  flow  and  particle 
deposition,  since particle deposition  was insensitive to  changes  in  many  variables.   Overall, 
COMSOL proved to be an invaluable tool to model a complex particle flow in the nasal cavity 
without time-intensive in vitro or in vivo experimentation using real spray formulations. 
Many  of  the  design  recommendations  of  this  study  are  pertinent  to  design  of  user-friendly 
packaging  for  nasal  sprays,  which  can  be  implemented  without  significant  cost  to  the 
manufacturer. We also showed that various drug formulations can be used, encompassing a large 
range of particle sizes and densities. Economical constraints of specific formulations should be 
considered. 
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6.  Appendix A: Mathematical Statement of the Problem 
Governing Equations 
(Inthavong et al. 2008) 
Air Flow – Continuity and Navier Stokes  
0 g gv
x
 
 
 
 
Particle Velocity – Lagrangian Particle Tracing 
 
 
 
 
Drag force per unit particle mass is described by the expression:    
where the units of Fd are in inverse time.  
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7.  Appendix B: Solution Strategy 
7.1 Detailed COMSOL Implementation 
Fluid Flow 
The fluid flow was modeled via the transient Navier Stokes equation for an incompressible fluid.  
Particle Motion 
To  model  the  motion  and  deposition  of  nasal  spray  droplets,  we  used  the  Particle  Tracing 
function of COMSOL (Figure 7), which can be found at: “Postprocessing > Plot Parameters > 
Particle Tracing.”  
 
Figure  7.  Particle  Tracing  Menus.  (a)  Particle  Tracing  tab  in  Postprocessing  >  Plot  Parameters.  Clicking  on  the 
"Advanced..."  button  brings  up  the  (b)  Advanced  Parameters window,  in  which  we  can  decrease  the  Resolution  to 
decrease computation time. 
7.2 Mesh Convergence 
Mesh convergence analysis (Figure 8) was performed by calculating the average x-component of 
air velocity in the nasal cavity model in COMSOL, at time t = 0.2 seconds. We chose an early 
time because the nasal deposition modeled by COMSOL particle tracing was a transient process, 
and we found that the particles were deposited within the first second of airflow. Furthermore, 
(a)  (b)  
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0.2 seconds is the time before the model reaches steady state air flow patterns, and thus contains 
the most variability. We chose to use the x-component of air velocity because it contains the 
most variability, as well as for ease of calculation. 
 
Average  x-component  of  air  velocity  was  found  by  using  the  Postprocessing  Subdomain 
Integration function of COMSOL (Datta and Rakesh 2008). For each mesh, we performed the 
following subdomain integration: (1) Expression: U_ns, Subdomain: all; and (2) Expression: 1, 
Subdomain: all (area integral). The average air velocity was calculated as 
 
We found that a mesh of 6476 elements was the coarsest mesh to show convergence (Figure 8).  
Due to memory constraints, however, the mesh with 4624 elements was used in this simulation. 
  
 
Figure 8. Mesh convergence of average air velocity in the nasal cavity at time t=0.2 seconds. 
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8.  Appendix C: Results 
 
Figure 9. Fluid velocity change with time. This air velocity graph is taken at point (0.03, 0.02) in our model, a point at the 
interface between the anterior and turbinate regions. At this location, the fluid velocity pattern reaches steady state after 
only 0.4 seconds of simulation.    
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Figure 10. Surface plot with particle tracing after 2 seconds of simulation. The black lines show the trajectories of the 
particles  and  the  pink  circles  show  the  final  deposition  location.  In  this  baseline  condition,  most  particle  deposition 
occurred in the anterior region. 
 
Figure 11. Magnified image of the anterior region at baseline. Due to the air flow and no slip condition at the walls, 
particles have become trapped in eddy currents caused by the nasal geometry.  
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Figure 12. Magnified image of the posterior and outlet regions at baseline. Due to the air flow and no slip condition at the 
walls, particles have become trapped in eddy currents caused by the nasal geometry. Other particles have been carried 
through the entire cavity to the outlet, and would proceed to the pharynx. 
 
 
Figure 13. Surface plot with particle tracing at an increased penetration depth. An increase in penetration depth results in 
an increase in the percentage of particles that are carried to the outlet, and a decrease in deposition in the anterior region.  
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